PA
EMBC icon

PharVision Advisers’s Embecta EMBC Stock Holding History

PharVision Advisers’s Portfolio EMBC Stock Details EMBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$140K Buy
15,877
+4,642
+41% +$48.4K 1.42% 16
2025
Q4 		$133K Buy
+11,235
New +$148K 0.07% 630

Other funds holding EMBC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
YAM
Yacktman Asset Management Austin, Texas $7.5B AUM 22.48% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PharVision Advisers's EMBC Position: Q1 2026 in Review

PharVision Advisers increased its Embecta (EMBC) stake by 41% in Q1 2026, buying an estimated $48.4K and bringing the position to 15,877 shares worth $140K. The position accounts for 1.42% of the portfolio, ranked #16.

PharVision Advisers first reported a position in EMBC in Q4 2025 and has held it in 2 quarters since. 337 funds tracked by Wall St. Rank hold EMBC as of Q1 2026.

  • PharVision Advisers held 15,877 shares of Embecta worth $140K as of Q1 2026.
  • PharVision Advisers bought 4,642 Embecta shares in Q1 2026, an estimated $48.4K.
  • Embecta made up 1.42% of PharVision Advisers's portfolio in Q1 2026, its #16 holding.
  • PharVision Advisers first reported a position in Embecta in Q4 2025 and has held it in 2 quarters since.
  • 337 funds tracked by Wall St. Rank held Embecta as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.